06/23/2026
𝐋𝐞𝐭 𝐦𝐞 𝐛𝐞 𝐟𝐚𝐢𝐫 𝐭𝐨 𝐭𝐡𝐞 𝐝𝐫𝐮𝐠 𝐛𝐞𝐟𝐨𝐫𝐞 𝐈 𝐭𝐚𝐤𝐞 𝐢𝐭 𝐚𝐩𝐚𝐫𝐭.
For people with type 2 diabetes and real heart or kidney disease, GLP-1 medications are not hype. They are treatment.
The FLOW trial was stopped early because semaglutide cut the risk of kidney disease progression, kidney failure, or related death by 24 percent in patients with diabetes and chronic kidney disease.
A review of 13 cardiovascular trials covering more than 83,000 patients found fewer heart attacks, fewer strokes, and lower all-cause mortality.
If your doctor prescribed this for one of those conditions, you are not being fooled. You are being treated.
But that is not who most people reaching for these drugs are. More on that tomorrow.
Decline is not inevitable.